Fenwick & West Represents ProNAi Therapeutics in $158.4 Million Initial Public Offering

Fenwick & West represented ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform, in its initial public offering. The company announced the closing of its initial public offering of 9,315,000 shares of its common stock at the public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,215,000 shares of common stock.

Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. Wedbuh and PacGrow and SunTrust Robinson Humphrey acted as co-managers.

The Fenwick transaction team included corporate attorneys Stephen Graham, Robert Freedman, James Evans, Amanda Rose and Tim Lee; executive compensation and employee benefits attorneys Scott Spector, Blake Martell and Laura McIntyre; technology transactions attorney Jake Handy; intellectual property attorneys Michael Shuster, Christine Redfield and Kevin Kabler and paralegal Ellen Welichko.